Codexis (CDXS) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
18 Jun, 2026Opening remarks and agenda
The meeting commenced at 9:00 A.M. Pacific Time on June 17, 2026, chaired by the CEO and held virtually via Broadridge Financial Solutions.
Key executives, board members, legal counsel, and the independent auditor were introduced as present.
Cheryl Niebling was appointed as Inspector of Election, having taken the oath earlier that day.
The agenda included four proposals, with voting procedures and rules of conduct outlined for participants.
Board and executive committee updates
The board and senior management, including the CEO and CFO, were present to address questions and oversee proceedings.
Shareholder proposals
Four proposals were presented: election of three Class 1 directors, ratification of KPMG LLP as auditor, and a non-binding advisory vote on executive compensation.
The advisory vote on executive compensation will inform future decisions by the Compensation Committee and Board.
Latest events from Codexis
- Q2 2026 saw $14.9M revenue, improved margins, and a $25M equity raise supporting future growth.CDXS
Q2 2026 - ECO Synthesis enables scalable, sustainable RNA manufacturing, meeting surging siRNA demand.CDXS
Corporate presentation - Q1 2026 revenue doubled, net loss narrowed, and cash reserves support ongoing growth.CDXS
Q1 2026 - Annual meeting to vote on directors, auditor, and executive pay, with board support for all proposals.CDXS
Proxy filing - Key votes include director elections, auditor ratification, and executive pay approval.CDXS
Proxy filing - 2025 revenue up 19% to $70.4M, Q4 profitable, 2026 outlook strong with $72–76M guidance.CDXS
Q4 2025 - ECO Synthesis platform drives RNA medicine manufacturing growth, targeting a $2B market by 2030.CDXS
TD Cowen 46th Annual Health Care Conference - Enzymatic siRNA manufacturing platform targets major market growth, with breakeven eyed by 2026.CDXS
Stifel 2024 Healthcare Conference - Q2 revenue met expectations; guidance and double-digit growth outlook reaffirmed.CDXS
Q2 2024